Skip to content
HeyJared

RealPharma: Conversations with Pharma Pathfinders

For biopharma pros seeking insightful discussions and a deeper understanding of the pharma world, join Dr. Na-Ri Oh and Ian Wendt as they talk with industry leaders and luminaries to delve into biotechnology, pharmaceuticals, and healthcare.

Podcast · By RealPharma · American English · Official site

Indexed episodes, last 90 days
3
Latest publication
Sep 8, 2026
Audience
Checking…
Earliest in this view
Jul 10, 2026

Latest episodes

  1. Episode · Sep 8, 2026

    Let’s Talk About Mold - with Ariana Thacker (opens the original)

    Episode notes · Neutral tone

    Read excerpt

    The Mold Blind Spot: Ariana Thacker on Building the First Scalable Model of Care for CIRS Real Pharma, hosted by Na-Ri Oh and Ian Wendt Episode Summary Somewhere between one in four Americans carries a genetic profile that makes it hard to clear biotoxins from the body, and there is still no dedicated ICD-10 code for the illness that can follow. In this episode, Na-Ri and Ian talk with Ariana Thacker, founder and CEO of MoldCo, about how a mystery illness and a mold inspection turned a venture c

  2. Episode · Aug 17, 2026

    From Patient Involvement to Patient Leadership - Donna Cryer, JD and Chief Patient Officer (opens the original)

    Episode notes · Neutral tone

    Read excerpt

    From Patient Involvement to Patient Leadership: A Conversation with Donna Cryer, JD Real Pharma, hosted by Na-Ri Oh and Ian Wendt Episode Summary As AI moves deeper into drug development, from trial design to evidence generation, the more pressing question isn't what the technology can do. It's who has the authority to decide how it's used. In this episode, Na-Ri and Ian sit down with Donna Cryer, JD, founder of the Global Liver Institute, longtime FDA patient representative, and the person cred

  3. Episode · Jul 10, 2026

    Good Intentions, Bad Outcomes: Rethinking Healthcare Policy with Deborah Williams (opens the original)

    Episode notes

    Read excerpt

    When Healthcare Policy Incentives Backfire: 340B, Hospital Pricing, MFN, and Drug Affordability with Deborah Williams Healthcare policies are often evaluated by what they are intended to accomplish. But what happens when the incentives created by those policies produce very different results? In this episode of RealPharma, Ian Wendt and Dr. Na-Ri Oh speak with longtime health policy expert Deborah Williams about the unintended consequences embedded in the U.S. healthcare system—from hospital rei

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

No verified audience measurement yet.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about RealPharma: Conversations with Pharma Pathfinders